HER2-POSITIVE EARLY BREAST CANCER
Clinical trials for HER2-POSITIVE EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to wipe out breast cancer before surgery
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd), given alone or with other treatments before surgery, in people with high-risk HER2-positive early breast cancer. The goal is to see if it can eliminate all signs of cancer by the time of surgery. About 927 adults with…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 04, 2026 16:21 UTC
-
Could a smarter drug replace harsh chemo for HER2+ breast cancer?
Disease control OngoingThis study tests whether a newer, targeted drug (T-DXd) works better than the usual chemotherapy cocktail for women with early-stage HER2-positive breast cancer. About 402 participants will receive either T-DXd or standard chemo before surgery. The goal is to see if T-DXd leads t…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: West German Study Group • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC